Koninklijke Philips NV

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: NL0000009538
EUR
23.48
-0.24 (-1.01%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.07 M

Shareholding (Dec 2025)

FII

0.16%

Held by 6 FIIs

DII

80.88%

Held by 18 DIIs

Promoter

18.96%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Weak Long Term Fundamental Strength with a 340.47% CAGR growth in Operating Profits over the last 5 years

  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 6,785.00 times
  • The company has reported losses. Due to this company has reported negative ROE
2

With ROE of 10.09%, it has a Very Expensive valuation with a 2.16 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 23,669 Million ()

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

16.68%

stock-summary
Debt Equity

0.37

stock-summary
Return on Equity

10.09%

stock-summary
Price to Book

2.16

Revenue and Profits:
Net Sales:
5,097 Million
(Quarterly Results - Dec 2025)
Net Profit:
393 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.25%
0%
3.25%
6 Months
2.13%
0%
2.13%
1 Year
-1.72%
0%
-1.72%
2 Years
29.27%
0%
29.27%
3 Years
54.31%
0%
54.31%
4 Years
-6.29%
0%
-6.29%
5 Years
-47.26%
0%
-47.26%

Koninklijke Philips NV for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
608.36%
EBIT Growth (5y)
340.47%
EBIT to Interest (avg)
1.97
Debt to EBITDA (avg)
6,127.67
Net Debt to Equity (avg)
0.55
Sales to Capital Employed (avg)
0.77
Tax Ratio
25.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
19.12%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
2.16
EV to EBIT
17.02
EV to EBITDA
10.14
EV to Capital Employed
1.82
EV to Sales
1.58
PEG Ratio
0.09
Dividend Yield
16.68%
ROCE (Latest)
10.70%
ROE (Latest)
10.09%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 6 Foreign Institutions (0.16%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 1.05% vs 0.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 182.56% vs -1,112.77% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,097.00",
          "val2": "5,044.00",
          "chgp": "1.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "926.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "109.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-91.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "393.00",
          "val2": "-476.00",
          "chgp": "182.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "126.90%",
          "val2": "0.00%",
          "chgp": "12.69%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -1.04% vs -0.81% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 207.02% vs -85.24% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "17,834.00",
          "val2": "18,021.00",
          "chgp": "-1.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,676.00",
          "val2": "2,397.00",
          "chgp": "11.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "290.00",
          "val2": "288.00",
          "chgp": "0.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-275.00",
          "val2": "-349.00",
          "chgp": "21.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "900.00",
          "val2": "-841.00",
          "chgp": "207.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "92.10%",
          "val2": "68.50%",
          "chgp": "2.36%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
5,097.00
5,044.00
1.05%
Operating Profit (PBDIT) excl Other Income
926.00
0.00
Interest
109.00
0.00
Exceptional Items
-91.00
0.00
Consolidate Net Profit
393.00
-476.00
182.56%
Operating Profit Margin (Excl OI)
126.90%
0.00%
12.69%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is 1.05% vs 0.00% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 182.56% vs -1,112.77% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
17,834.00
18,021.00
-1.04%
Operating Profit (PBDIT) excl Other Income
2,676.00
2,397.00
11.64%
Interest
290.00
288.00
0.69%
Exceptional Items
-275.00
-349.00
21.20%
Consolidate Net Profit
900.00
-841.00
207.02%
Operating Profit Margin (Excl OI)
92.10%
68.50%
2.36%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is -1.04% vs -0.81% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 207.02% vs -85.24% in Dec 2024

stock-summaryCompany CV
About Koninklijke Philips NV stock-summary
stock-summary
Koninklijke Philips NV
Pharmaceuticals & Biotechnology
Koninklijke Philips N.V. is the Netherlands-based health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.
Company Coordinates stock-summary
Company Details
Breitner Center, Amstelplein 2 , AMSTERDAM None : 1096 BC
stock-summary
Tel: 31 20 597777731 31 205977222
stock-summary
Registrar Details